K
Kailera
United States · $600.0M raised
- Employees
- 11–50
- Business Model
- B2B
- Total Funding
- $600.0M
About
Late clinical-stage biotechnology company advancing GLP-1 therapies for obesity and metabolic disease.
Summary
Kailera is a Biotech company based in United States. It has raised $600.0M in total.
Funding History
No funding data available yet.
Know something? Help us improve our data.
Similar Companies
PP
Pharmaceutical Product Development, Inc. (PPD)Acquired
Global contract research organization providing comprehensive drug development and laboratory ser...
Wilmington, United States10001+Biotech, Healthcare
Private Equity·$3.9B·Jan 2019
IVI-RMA
Global fertility clinics platform
Valencia, Spain5001–10000Biotech, Healthcare
Private Equity·$3.3B·Apr 2022
inVentiv HealthAcquired
Biopharmaceutical services company
Burlington, United States5001–10000Biotech, Healthcare
Private Equity·$3.0B·May 2017
Warner ChilcottClosed
Specialty pharmaceutical company
Rockaway, United States1001–5000Biotech, Healthcare
Private Equity·$3.0B·Jan 2004
Altos Labs
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
San Francisco, United States501–1000Life Sciences, Biotech
Series A·$3.0B·Jan 2022
BeiGeneIPO
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Cambridge, United States10001+Biotech, Oncology
Corporate Round·$2.8B·Jan 2020